All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2021
Details:
The data from the BE VIVID and BE READY studies demonstrated bimekizumab-treated patients achieved superior levels of skin clearance at week 16 compared to those who received placebo or Janssen’s Stelara (ustekinumab).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daxibotulinumtoxin A
Therapeutic Area: Dermatology Product Name: DaxibotulinumtoxinA
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Revance Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 22, 2020
Details:
Aji Bio-Pharma will operate as a dual source of supply and provide drug product manufacturing services to Revance for the supply of DaxibotulinumtoxinA for Injection at the company's aseptic manufacturing facility in San Diego, California.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2020
Details:
Data from the Phase 3 BE SURE study demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved significantly higher PASI 90 and PASI 100 skin clearance rates, compared to Humira®, at week 16.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
This accepted submission is supported by a robust data package including three Phase 3 studies which demonstrate superiority of bimekizumab to placebo, Stelara[®] (ustekinumab) and Humira[®] (adalimumab) in achieving skin clearance at week 16.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: UCB4940
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
BE RADIANT met its primary endpoint at week 16 with statistical significance, demonstrating the superiority of bimekizumab over secukinumab for complete skin clearance, as measured by a 100 percent improvement in the Psoriasis Area and Severity Index (PASI 100).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
